|
|
|
BCRX Description — BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
Company Name: |
BioCryst Pharmaceuticals Inc |
Website: |
www.biocryst.com |
Sector: |
Biotechnology |
Number of ETFs Holding BCRX: |
27 |
Total Market Value Held by ETFs: |
$162,134,980 |
Total Market Capitalization: |
$1,008,000,000 |
% of Market Cap. Held by ETFs: |
16.08% |
|
ETF |
BCRX Weight |
BCRX Amount |
XBI |
0.58% |
$44,206,623 |
VTI |
0.00% |
$34,118,489 |
IWM |
0.04% |
$22,844,214 |
VXF |
0.02% |
$15,886,129 |
VB |
0.01% |
$12,842,494 |
VBK |
0.02% |
$7,173,179 |
IWO |
0.05% |
$6,188,844 |
LABU |
0.45% |
$5,045,101 |
VHT |
0.02% |
$3,133,482 |
VTWO |
0.04% |
$3,060,937 |
List of all 27 ETFs holding BCRX
» |
|
|
|
|
Strong Buy (3.50 out of 4)
60th percentile
|
|
|